Complication, Gastric Cancer, Malnutrition; Cachexia, Sarcopenia
Conditions
Keywords
sarcopenia, cancer, gastrointestinal
Brief summary
We aimed to establish the effects of sarcopenia on postoperative complications among patients undergoing surgical treatment for gastric cancer
Detailed description
Among gastrointestinal disease, gastric cancer is a malignancy which is diagnosed predominantly in advanced stages, mostly accompanied with malnutrition when diagnosed, has aggressive behavior with poor oncological outcomes. The only option for curative treatment is surgical resection in this malignancy; however, the surgical procedure itself causes high morbidity and mortality rates. Therefore, physicians combine various treatment modalities and risk assessment to decrease complication and mortality rates. Sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength with a risk of adverse outcomes such as physical disability, poor quality of life, and death. For the diagnosis of sarcopenia, using the presence of both low muscle mass and decreased muscle function (strength or performance) is recommended. Previous studies showed that colorectal or pancreatic cancer accompanied with sarcopenia has adverse effects on not only for short term and also for long term outcomes. The majority of studies regarding gastric cancer was published from Eastern countries owing to their high incidence. There are few studies from western countries which are mostly retrospective and does not meet the diagnostic criteria of sarcopenia. In the western population, there is no high-quality evidence so far regarding the impact of sarcopenia on early outcomes of gastric cancer surgical treatment.
Interventions
OTHERNo intervention
No intervention is planned for the participants for the treatment of gastric cancer. Treatment decision will be in line with clinical practice guidelines. Surgical team will be blind to the participant's sarcopenia status.
Sponsors
Karadeniz Technical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients undergoing gastric surgery for gastric cancer 2. Histologically proven gastric adenocarcinoma 3. Patients over 18 years 4. Patients who agreed to participate in the study
Exclusion criteria
1. patients treated by non-surgical treatment such as endoscopic treatment, palliative chemotherapy) 2. patients received palliative surgery without gastric resection (bypass procedures) 3. patients required thoracotomy/thoracoscopy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative complications | within 30 days after surgery | complications graded by Clavien-Dindo Complication Classification System |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | within 30 days after surgery | Dying after surgery |
| Readmission rate | within 30 days after surgery | readmission to the hospital because of the adverse events after discharge |
| Incidence of sarcopenia | one day before surgery | Sarcopenia consensus defined by The European Working Group on Sarcopenia in Older People |
| Muscle mass volume | one day before surgery | muscle mass volume of a cross-sectional computerized- tomography image of the L3, corrected for patient height resulting in L3 muscle index. |
| Length of hospital stay | up to 90 days | time interval from the date of operation to the date of discharge |
| Muscle strength | one day before surgery | evaluated by handgrip strength test (with digital dynamometer) |
| Physical performance | one day before surgery | evaluated by 4-meter gait speed test |
| Major complication | within 30 days after surgery | grade 3 or higher complications graded by Clavien-Dindo Complication Classification System |
| Psoas muscle mass volume | one day before surgery | muscle mass volume of Psoas muscle with 3D reconstruction |
Countries
Turkey (Türkiye)
Outcome results
None listed